Publicaciones en las que colabora con Felipe Prósper Cardoso (55)

2023

  1. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924

  2. Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    Cancer Medicine, Vol. 12, Núm. 4, pp. 3999-4009

  3. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

  4. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

  5. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution

    eLife, Vol. 12

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

  2. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

    European Journal of Cancer, Vol. 174, pp. 243-250

  3. Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome

    Frontiers in Immunology, Vol. 13

  4. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

  5. Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes

    Leukemia and Lymphoma, Vol. 63, Núm. 5, pp. 1227-1235

  6. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

    Nature Communications, Vol. 13, Núm. 1

2021

  1. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

    Leukemia, Vol. 35, Núm. 1, pp. 245-249

  2. Long-term efficacy of autologous bone marrow mesenchymal stromal cells for treatment of knee osteoarthritis

    Journal of Translational Medicine

  3. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

  4. The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial

    Cancers, Vol. 13, Núm. 10

  5. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2020

  1. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

    EClinicalMedicine, Vol. 25

  2. Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design

    PLoS ONE, Vol. 15, Núm. 1

  3. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

    Leukemia, Vol. 34, Núm. 11, pp. 3007-3018

  4. Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

    Frontiers in Immunology